Completed PHASE2 INTERVENTIONAL 1-arm NCT01045772

Safety and Tolerability of Rilonacept in Muckle-Wells Syndrome (MWS) or Schnitzler Syndrome (SchS) (ACCILTRA1)

A Single-Centre, Open Label Study of the Safety and Tolerability of Rilonacept in Subjects Living in Germany With Muckle-Wells Syndrome (MWS), a Cryopyrin-Associated Periodic Syndrome (CAPS), or Schnitzler Syndrome (SchS)

Sponsor: Charite University, Berlin, Germany

Conditions Muckle-Wells Syndrome Schnitzler Syndrome

Interventions rilonacept

Updated 5 times since 2017 Last updated: May 30, 2012 Started: Jan 31, 2009 Primary completion: Sep 30, 2010 Completion: Sep 30, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01045772, this PHASE2 trial focuses on Muckle-Wells Syndrome and Schnitzler Syndrome and remains completed. Sponsored by Charite University, Berlin, Germany, it has been updated 5 times since 2009, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jan 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Charite University, Berlin, Germany

Data source: Charite University, Berlin, Germany

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Berlin, Germany